## ZimVie (ZIMV) Earnings Preview: What to Expect on October 30th
Investors are gearing up for ZimVie Inc. (ZIMV)’s upcoming quarterly earnings report, scheduled for Wednesday, October 30th, 2024. The market is buzzing with anticipation, hoping for a positive surprise from the dental and spine solutions provider.
Analysts are predicting an earnings per share (EPS) of $0.07. However, it’s not just about meeting expectations. Investors are also keen to hear about ZimVie’s outlook for the next quarter. Strong guidance could significantly influence stock prices, making this announcement a critical event for ZIMV shareholders.
### A Look Back: ZimVie’s Past Earnings Performance
ZimVie’s recent history with earnings reports has been a mixed bag. Last quarter, the company missed EPS estimates by $0.04, leading to a 15.2% drop in share price the following day. This highlights the sensitivity of ZIMV shares to earnings results.
Here’s a closer look at ZimVie’s past performance and the subsequent price changes:
| Quarter | EPS Estimate | EPS Actual | Price Change % |
|—|—|—|—|
| Q2 2024 | $0.17 | $0.13 | -15.0% |
| Q1 2024 | -$0.04 | $0.08 | 10.0% |
| Q4 2023 | $0.12 | $0.10 | -14.000000000000002% |
| Q3 2023 | -$0.02 | $0.08 | 11.0% |
### Positive Momentum: Long-Term Shareholder Sentiment
Despite past volatility, ZIMV shares have performed well over the long term. As of October 28th, shares were trading at $13.98, a significant 103.71% increase over the last 52 weeks. This positive trend likely fuels optimism among long-term shareholders going into this earnings release.
### What Analysts Say: Insights into ZimVie’s Future
For investors, understanding market sentiment and expectations is crucial. Analysts have provided ZimVie with 1 rating, resulting in a consensus rating of Buy. The average one-year price target is set at $23.0, suggesting a potential 64.52% upside.
### Comparing ZimVie to Its Peers
To gauge ZimVie’s performance relative to its competitors, let’s look at analyst ratings and average one-year price targets for three prominent players in the industry: ClearPoint Neuro, Butterfly Network, and Paragon 28.
*
ClearPoint Neuro:
Consensus rating: Buy; Average 1-year price target: $15.0 (7.3% upside)*
Butterfly Network:
Consensus rating: Buy; Average 1-year price target: $3.0 (78.54% downside)*
Paragon 28:
Consensus rating: Buy; Average 1-year price target: $11.5 (17.74% downside)### Financial Performance: A Detailed Look
ZimVie’s business is organized into two segments: spine products and dental products. Here’s a breakdown of the company’s financial performance compared to its peers:
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|—|—|—|—|—|
| ZimVie | Buy | -1.55% | $73.29M | -1.03% |
| ClearPoint Neuro | Buy | 32.07% | $4.99M | -13.21% |
| Butterfly Network | Buy | 16.23% | $12.59M | -7.89% |
| Paragon 28 | Buy | 19.62% | $45.76M | -8.85% |
Key Takeaway:
While ZimVie boasts a strong Return on Equity, its revenue growth and gross profit margin lag behind its peers. This indicates potential challenges in maintaining financial momentum.### Understanding ZimVie’s Strengths and Weaknesses
Market Capitalization:
ZimVie’s market capitalization is below industry averages, suggesting a smaller scale compared to its competitors.Revenue Trend:
Over the past three months, ZimVie experienced a -1.55% decline in revenue growth, indicating a decrease in top-line earnings.Net Margin:
Despite revenue challenges, ZimVie maintains an exceptional net margin of -3.44%, showcasing effective cost management and strong profitability.Return on Equity (ROE):
ZimVie’s ROE of -1.03% surpasses industry averages, highlighting its effective utilization of equity capital.Return on Assets (ROA):
ZimVie’s ROA also exceeds industry benchmarks at -0.41%, demonstrating efficient asset management and strong financial health.Debt Management:
The company maintains a balanced debt approach, with a debt-to-equity ratio below industry norms at 0.63.Focus on Growth:
ZimVie is actively pursuing growth in the dental and spine markets. The company is focused on implant solutions, surgical tools, bone graft substitutes, spinal fusion implants, and digital care management solutions.### Conclusion: Looking Ahead
Investors will be closely watching ZimVie’s earnings announcement on October 30th. While past performance has been volatile, long-term growth potential remains evident. The key factors to watch will be the company’s earnings performance, guidance for the next quarter, and its ongoing efforts to navigate competitive pressures and drive revenue growth. Stay tuned for a detailed analysis of the earnings report once it is released.
